Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer | NEJM
Event-free survival > Overall survival? - data analysis - Datamethods Discussion Forum
Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - Journal of Thoracic Oncology
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points - Annals of Oncology
Disease Free Survival - an overview | ScienceDirect Topics
Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low–middle-income country | SpringerLink
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download
OP0294 SJÖGREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND 10-YEAR SURVIVAL | Annals of the Rheumatic Diseases
BrighTNess Neoadjuvant Carboplatin Improves Event-Free Survival in Triple-Negative Breast Cancer - The ASCO Post
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial - Annals of
Progression-free survival (PFS), event-free survival (EFS), and overall... | Download Scientific Diagram
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children | NEJM
Kaplan Meier plots, showing the difference in overall survival, event... | Download Scientific Diagram
Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia - Tsimberidou - 2008 - Cancer - Wiley Online Library
Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials - European Journal of Cancer
Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation | Journal of Clinical Oncology
Survival analysis in hematologic malignancies: recommendations for clinicians | Haematologica
Cancers | Free Full-Text | Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma | HTML
Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná | Hematology, Transfusion and Cell Therapy
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation - Biology of Blood and Marrow Transplantation
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The
